Publications

Brown JC, Zhang S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Li Y, Zhang X, Ng K, Willett WC, Giovannucci EL, Fuchs CS, Meyerhardt JA. Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI cancer spectrum. 2018. PMID: 29877501

Singh KP, Kober KM, Dhruva AA, Flowers E, Paul SM, Hammer MJ, Cartwright F, Wright F, Conley YP, Levine JD, Miaskowski C. Risk Factors Associated With Chemotherapy-Induced Nausea in the Week Before the Next Cycle and Impact of Nausea on Quality of Life Outcomes. Journal of pain and symptom management. 2018. PMID: 29857180

Chari A, Bhor M, Eldjerou L, Gilligan AM, Urniasz A, Globe D, Stetsovsky D, Varker H, Davis B, Bonafede M, Talcott J. Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat. Future oncology (London, England). 2018. PMID: 29846095

Hecht FM, Moskowitz JT, Moran P, Epel ES, Bacchetti P, Acree M, Kemeny ME, Mendes WB, Duncan LG, Weng H, Levy JA, Deeks SG, Folkman S. A randomized, controlled trial of mindfulness-based stress reduction in HIV infection. Brain, behavior, and immunity. 2018. PMID: 29842903

Ellsworth GB, Lensing SY, Ogilvie CB, Lee JY, Goldstone SE, Berry-Lawhorn JM, Jay N, Stier EA, Logan JS, Einstein MH, Saah A, Mitsuyasu RT, Aboulafia D, Palefsky JM, Wilkin TJ. A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men. Papillomavirus research (Amsterdam, Netherlands). 2018. PMID: 29807211

Spinner MA, Advani RH, Connors JM, Azzi J, Diefenbach C. New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little? American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2018. PMID: 30231319

Krastev DB, Pettitt SJ, Campbell J, Song F, Tanos BE, Stoynov SS, Ashworth A, Lord CJ. Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets. Nature communications. 2018. PMID: 29789535

Snyder RA, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, Van Loon K, You YN, Kozower BD, Greenberg CC, Schrag D, Venook A, McKellar D, Winchester DP, Chang GJ, Alliance for Clinical Trials in Oncology Network Cancer Surveillance Optimization Working Group. Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer. JAMA. 2018. PMID: 29800181

Evan Justin Walker, Julia C. Carnevale, Christina Pedley, Amie Blanco, Salina Chan, Eric Andrew Collisson, Andrew H. Ko. Referral patterns and attrition rate for germline testing in pancreatic cancer (PC) patients. Journal of Clinical Oncology. 2018. PMID:

Sara Nunnery, Dorothy Wang, Marisela Tan, Richard Fong, Mimi Ming Lo, Rebecca L. Olin. Efficacy and cost-effectiveness of clofarabine with high-dose cytarabine for treatment of relapsed/refractory acute myeloid leukemia (R/R AML). Journal of Clinical Oncology. 2018. PMID:

Mariam T. Nawas, Charalambos Andreadis, Thomas G. Martin, Jeffrey Lee Wolf, Weiyun Z. Ai, Lawrence D. Kaplan, Gabriel N. Mannis, Aaron Logan, Lloyd Earl Damon, Chiung-Yu Huang, Rebecca L. Olin. Impact of patient reported functional limitation on overall survival in older adults undergoing autologous hematopoietic cell transplant (AutoHCT). Journal of Clinical Oncology. 2018. PMID:

Mark J. Levis, Catherine Choy Smith, Koji Ishizuka, Ken Kobayashi, Meena Arunachalam, Yibin Wang, Deborah Lazzaretto, Jorge E. Cortes. Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3 -ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment. Journal of Clinical Oncology. 2018. PMID:

Kartoun U, Aggarwal R, Beam AL, Pai JK, Chatterjee AK, Fitzgerald TP, Kohane IS, Shaw SY. Development of an Algorithm to Identify Patients with Physician-Documented Insomnia. Scientific Reports. 2018. PMID: 29777125

Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ. Reply to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study". British journal of cancer. 2018. PMID: 29769747

Rosko AE, Olin RL, Artz A, Wildes TM, Stauder R, Klepin HD. A call to action in hematologic disorders: A report from the ASH scientific workshop on hematology and aging. Journal of geriatric oncology. 2018. PMID: 29759912

Von Hoff DD, Rasco DW, Heath EI, Munster PN, Schellens JHM, Isambert N, Le Tourneau C, O'Neil B, Mathijssen RHJ, Lopez-Martin JA, Edenfield WJ, Martin M, LoRusso PM, Bray GL, DiMartino J, Nguyen A, Liu K, Laille E, Bendell JC. Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018. PMID: 29764853

Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. European urology oncology. 2018. PMID: 31100231

Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L, Plymate SR, Praet SFE, Guinan EM, Van Blarigan EL, Casey O, Buzza M, Gledhill S, Zhang L, Galvão DA, Ryan CJ, Saad F. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ open. 2018. PMID: 29764892

Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3. Cancer research. 2018. PMID: 29760043

Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nature communications. 2018. PMID: 29748565